BaroSense develops minimally-invasive therapeutic weight loss procedures, devices and surgical treatments for the obese.
BaroSense is committed to develop and commercialize novel anti-obesity products that provide a meaningful contribution to this leading healthcare problem facing the United States today. BaroSense was conceived in order to create a safe, simple, effective, and minimally invasive alternative to the surgical treatment of obesity - an innovative approach to assist those people who need help beyond traditional diets, and who wish to avoid extensive, irreversible surgery.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Aug 24, 2009 | Series D | $27M | 1 | — | — | Detail |
Dec 5, 2007 | Series C | $11.20M | 1 | — | — | Detail |
Dec 22, 2004 | Series B | $6.20M | 1 | — | — | Detail |